Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

Bluejay Diagnostics (NASDAQ:BJDX) will implement a board-approved 1-for-4 reverse stock split effective November 3, 2026, at 12:01 a.m. Eastern Time.

Rhea-AI Summary

Bluejay Diagnostics (NASDAQ:BJDX) will implement a board-approved 1-for-4 reverse stock split effective November 3, 2026, at 12:01 a.m. Eastern Time.

Split-adjusted trading will begin on The Nasdaq Capital Market that day. Outstanding common shares will decrease from approximately 4,468,051 to 1,117,013, while common shares issuable upon exercise of prefunded warrants will decrease from 222,581 to 55,645. Shares underlying outstanding equity awards and warrants will also be adjusted. Ownership percentages will remain unchanged except for adjustments arising from fractional shares, which will be paid in cash rather than issued.

Argus 15 min delay 11 alerts

-7.05% vs previous close $0.50 last price 2.3x rel. volume Open Argus

Details

Market move: BJDX -7.05% vs previous close. 1-for-4 reverse stock split

+8.2% Peak Tracked

-10.4% Trough Tracked

$0.46 – $0.56 Day Range

$2.24M Mkt Cap at Last Price

On Oct 30, the day this news came out, the latest delayed price for BJDX is 7.05% below the previous close. Argus tracked a peak move of +8.2% during the session. Argus tracked a trough of -10.4% from its starting point during tracking. Our momentum scanner has recorded 11 alerts for this stock so far that day. The latest delayed price is $0.50. Relative volume is elevated at 2.3x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Reverse stock split ratio: 1-for-4 Effective time: 12:01 a.m. Eastern Time, November 3, 2026 Prefunded warrant shares: 222,581 to 55,645 shares +1 more

Reverse stock split ratio

1-for-4

Approved by the board

Effective time

12:01 a.m. Eastern Time, November 3, 2026

Post-split trading begins November 3, 2026

Prefunded warrant shares

222,581 to 55,645 shares

Shares issuable upon exercise, before and after the split

Par value

$0.0001 per share

Unchanged by the reverse stock split

Previous Stock split Reports

1 past event · Latest: Jan 27

Same Type 1 event

1. Jan 27

   Reverse split

   24h Move

   -3.9%

   Prior announcement disclosed an identical 1-for-4 ratio and post-split share consolidation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cusip number, prefunded warrants, par value

3 terms

cusip number technical

"common stock will also commence trading with a new CUSIP number"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

prefunded warrants financial

"shares of the Company's common stock issuable upon the exercise of prefunded warrants"

Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.

par value financial

"with no change to the par value of $0.0001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ACTON, MA / ACCESS Newswire / October 30, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony^™ near-patient diagnostic platform, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 3, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 3, 2026 under the Company's existing trading symbol, "BJDX." At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633707.

At the effective time of the reverse stock split, every four (4) issued and outstanding shares of Bluejay common stock will be combined into one (1) share of common stock, with no change to the par value of $0.0001 per share. This will reduce the Company's outstanding common stock from approximately 4,468,051 shares to approximately 1,117,013 shares (and reduce the number of shares of the Company's common stock issuable upon the exercise of prefunded warrants from 222,581 to 55,645). No fractional shares of common stock will be issued as a result of the reverse stock split and instead holders of Bluejay common stock will receive a cash payment in lieu of fractional shares to which they would otherwise be entitled. The shares underlying the Company's outstanding equity awards and warrants will also be adjusted accordingly. The reverse stock split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's common stock, except for adjustments that may result from the treatment of fractional shares.

The Company has retained its transfer agent, Continental Stock Transfer & Trust Company ("Continental"), to act as its exchange agent for the reverse stock split. Stockholders with shares held in certificate form will receive from Continental instructions regarding the exchange of their certificates. Stockholders that hold shares in book-entry form or hold their shares in brokerage accounts are not required to take any action and will see the impact of the reverse stock split reflected in their accounts, subject to brokers' particular processes. Beneficial holders of Bluejay common stock are encouraged to contact their bank, broker, custodian or other nominee with questions regarding procedures for processing the reverse stock split.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony^™ System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony^™ System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony^™ can be marketed as a diagnostic product in the United States. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

Forward-Looking Statements:

This press release contains statements that the Company believes are "forward-looking statements" within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "suggest," "will," and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, "Risk Factors" in its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026 and June 30, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company's expectations of results or any future change in events, except as required by law.

Investor Contact:

Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310
Website: www.bluejaydx.com

SOURCE: Bluejay Diagnostics

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Bluejay Diagnostics' reverse stock split take effect, and what is the ratio?

Bluejay's 1-for-4 reverse stock split takes effect at 12:01 a.m. Eastern Time on November 3, 2026. Every four issued and outstanding common shares will become one share. Split-adjusted trading on The Nasdaq Capital Market begins that day under the existing symbol BJDX.

Do Bluejay Diagnostics shareholders need to exchange their shares for the reverse split?

Shareholders holding certificates will receive exchange instructions from Continental Stock Transfer & Trust Company; holders in book-entry form or brokerage accounts need not take action. Brokerage account adjustments remain subject to brokers' particular processes. Beneficial holders can contact their bank, broker, custodian or other nominee with processing questions.